{"title":"宫颈癌进展与微生物组的关系分析。","authors":"Yue-Yue Gao, Xiao-Xue Li, Hui Zuo, Ping Zhang","doi":"10.2147/IJGM.S520936","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer remains a leading malignancy among women worldwide. Emerging evidence suggests that alterations in the cervical microbiota may influence its development and progression.</p><p><strong>Objective: </strong>To compare the cervical microbiota composition and diversity between cervical cancer patients and healthy women using 16S rRNA gene sequencing.</p><p><strong>Methods: </strong>Between January and June 2024, cervical tissue samples were collected from 40 cervical cancer patients and 40 healthy women. Microbial DNA was extracted and the V3-V4 region of the 16S rRNA gene was sequenced using the Illumina Novaseq 6000 platform. QIIME2 and R software were used for microbial classification and diversity analysis. LEfSe was applied to identify differentially abundant taxa between groups.</p><p><strong>Results: </strong>At the phylum level, <i>Firmicutes</i> dominated the control group (67.91%), while dropped to 31.03% in cervical cancer patients. <i>Actinobacteria</i> (26.22% vs 14.37%) and <i>Proteobacteria</i> (27.61% vs 0.72%) were significantly elevated in the cancer group. At the genus level, <i>Lactobacillus</i> was predominant in controls (46.27%), while reduced in patients, and Rhodococcus and Klebsiella were notably enriched. Alpha diversity (Shannon index) exhibited no significant difference between groups, whereas richness indices (Chao1 and ACE) were significantly higher in the cancer group (p < 0.05). Beta diversity analysis revealed a clear distinction in community structure (t = 10.225, P = 0.001). LEfSe identified Rhodococcus (LDA = 5.24), Klebsiella (LDA = 5.17), and Ralstonia as significantly more abundant in the cancer group, while <i>Firmicutes</i> (LDA = 5.31) was characteristic of the control group.</p><p><strong>Conclusion: </strong>Cervical cancer patients exhibited distinct cervical microbiota profiles, with reduced Firmicutes and elevated Actinobacteria and Proteobacteria. Increased levels of Rhodococcus and Klebsiella suggested a potential association between microbial dysbiosis and cervical cancer. These findings highlight the microbiome's relevance to tumor biology and support further investigation into its diagnostic and therapeutic potential.</p>","PeriodicalId":14131,"journal":{"name":"International Journal of General Medicine","volume":"18 ","pages":"2449-2460"},"PeriodicalIF":2.1000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067470/pdf/","citationCount":"0","resultStr":"{\"title\":\"Analysis of the Relationship Between Cervical Cancer Progression and the Microbiome.\",\"authors\":\"Yue-Yue Gao, Xiao-Xue Li, Hui Zuo, Ping Zhang\",\"doi\":\"10.2147/IJGM.S520936\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Cervical cancer remains a leading malignancy among women worldwide. Emerging evidence suggests that alterations in the cervical microbiota may influence its development and progression.</p><p><strong>Objective: </strong>To compare the cervical microbiota composition and diversity between cervical cancer patients and healthy women using 16S rRNA gene sequencing.</p><p><strong>Methods: </strong>Between January and June 2024, cervical tissue samples were collected from 40 cervical cancer patients and 40 healthy women. Microbial DNA was extracted and the V3-V4 region of the 16S rRNA gene was sequenced using the Illumina Novaseq 6000 platform. QIIME2 and R software were used for microbial classification and diversity analysis. LEfSe was applied to identify differentially abundant taxa between groups.</p><p><strong>Results: </strong>At the phylum level, <i>Firmicutes</i> dominated the control group (67.91%), while dropped to 31.03% in cervical cancer patients. <i>Actinobacteria</i> (26.22% vs 14.37%) and <i>Proteobacteria</i> (27.61% vs 0.72%) were significantly elevated in the cancer group. At the genus level, <i>Lactobacillus</i> was predominant in controls (46.27%), while reduced in patients, and Rhodococcus and Klebsiella were notably enriched. Alpha diversity (Shannon index) exhibited no significant difference between groups, whereas richness indices (Chao1 and ACE) were significantly higher in the cancer group (p < 0.05). Beta diversity analysis revealed a clear distinction in community structure (t = 10.225, P = 0.001). LEfSe identified Rhodococcus (LDA = 5.24), Klebsiella (LDA = 5.17), and Ralstonia as significantly more abundant in the cancer group, while <i>Firmicutes</i> (LDA = 5.31) was characteristic of the control group.</p><p><strong>Conclusion: </strong>Cervical cancer patients exhibited distinct cervical microbiota profiles, with reduced Firmicutes and elevated Actinobacteria and Proteobacteria. Increased levels of Rhodococcus and Klebsiella suggested a potential association between microbial dysbiosis and cervical cancer. These findings highlight the microbiome's relevance to tumor biology and support further investigation into its diagnostic and therapeutic potential.</p>\",\"PeriodicalId\":14131,\"journal\":{\"name\":\"International Journal of General Medicine\",\"volume\":\"18 \",\"pages\":\"2449-2460\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-05-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12067470/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of General Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/IJGM.S520936\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of General Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/IJGM.S520936","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
背景:宫颈癌仍然是世界范围内妇女的主要恶性肿瘤。新出现的证据表明,宫颈微生物群的改变可能影响其发展和进展。目的:应用16S rRNA基因测序技术比较宫颈癌患者与健康女性宫颈菌群组成及多样性。方法:于2024年1 - 6月分别采集40例宫颈癌患者和40例健康女性的宫颈组织标本。提取微生物DNA,利用Illumina Novaseq 6000平台对16S rRNA基因的V3-V4区进行测序。采用QIIME2和R软件进行微生物分类和多样性分析。利用LEfSe对不同类群间丰富度差异的分类群进行鉴定。结果:在门水平上,对照组以厚壁菌门为主(67.91%),而宫颈癌患者则降至31.03%。放线菌群(26.22% vs 14.37%)和变形菌群(27.61% vs 0.72%)在癌症组中显著升高。在属水平上,乳酸菌在对照组中占优势(46.27%),而在患者中则有所减少,红球菌和克雷伯菌显著富集。α多样性(Shannon指数)组间差异不显著,而丰富度指数(Chao1和ACE)组间差异显著(p < 0.05)。Beta多样性分析显示群落结构差异明显(t = 10.225, P = 0.001)。LEfSe鉴定出红球菌(LDA = 5.24)、克雷伯氏菌(LDA = 5.17)和Ralstonia在癌症组中含量显著增加,而厚壁菌门(LDA = 5.31)在对照组中含量显著增加。结论:宫颈癌患者表现出明显的宫颈菌群特征,厚壁菌门减少,放线菌门和变形菌门升高。红球菌和克雷伯氏菌水平的升高表明微生物生态失调与宫颈癌之间存在潜在的联系。这些发现突出了微生物组与肿瘤生物学的相关性,并支持进一步研究其诊断和治疗潜力。
Analysis of the Relationship Between Cervical Cancer Progression and the Microbiome.
Background: Cervical cancer remains a leading malignancy among women worldwide. Emerging evidence suggests that alterations in the cervical microbiota may influence its development and progression.
Objective: To compare the cervical microbiota composition and diversity between cervical cancer patients and healthy women using 16S rRNA gene sequencing.
Methods: Between January and June 2024, cervical tissue samples were collected from 40 cervical cancer patients and 40 healthy women. Microbial DNA was extracted and the V3-V4 region of the 16S rRNA gene was sequenced using the Illumina Novaseq 6000 platform. QIIME2 and R software were used for microbial classification and diversity analysis. LEfSe was applied to identify differentially abundant taxa between groups.
Results: At the phylum level, Firmicutes dominated the control group (67.91%), while dropped to 31.03% in cervical cancer patients. Actinobacteria (26.22% vs 14.37%) and Proteobacteria (27.61% vs 0.72%) were significantly elevated in the cancer group. At the genus level, Lactobacillus was predominant in controls (46.27%), while reduced in patients, and Rhodococcus and Klebsiella were notably enriched. Alpha diversity (Shannon index) exhibited no significant difference between groups, whereas richness indices (Chao1 and ACE) were significantly higher in the cancer group (p < 0.05). Beta diversity analysis revealed a clear distinction in community structure (t = 10.225, P = 0.001). LEfSe identified Rhodococcus (LDA = 5.24), Klebsiella (LDA = 5.17), and Ralstonia as significantly more abundant in the cancer group, while Firmicutes (LDA = 5.31) was characteristic of the control group.
Conclusion: Cervical cancer patients exhibited distinct cervical microbiota profiles, with reduced Firmicutes and elevated Actinobacteria and Proteobacteria. Increased levels of Rhodococcus and Klebsiella suggested a potential association between microbial dysbiosis and cervical cancer. These findings highlight the microbiome's relevance to tumor biology and support further investigation into its diagnostic and therapeutic potential.
期刊介绍:
The International Journal of General Medicine is an international, peer-reviewed, open access journal that focuses on general and internal medicine, pathogenesis, epidemiology, diagnosis, monitoring and treatment protocols. The journal is characterized by the rapid reporting of reviews, original research and clinical studies across all disease areas.
A key focus of the journal is the elucidation of disease processes and management protocols resulting in improved outcomes for the patient. Patient perspectives such as satisfaction, quality of life, health literacy and communication and their role in developing new healthcare programs and optimizing clinical outcomes are major areas of interest for the journal.
As of 1st April 2019, the International Journal of General Medicine will no longer consider meta-analyses for publication.